Other substances

CAP-1002

allogeneic cardiosphere-derived cells

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series	Patients			May/12/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04338347	CAP-1002 in Severe COVID-19 Disease	No longer available		Jan/01/1970	Jan/01/1970
Alternative id - CAP-1002-COVID-19 Interventions - Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells Study type - Expanded Access:Intermediate-size Population\|Treatment IND/Protocol Study results - No Results Available Locations - Cedars-Sinai Medical Center, Los Angeles, California, United States Study designs - Enrollment - Age - 18 Years and older (Adult, Older Adult) Outcome measures -
NCT04623671	Intravenous Infusion of CAP-1002 in Patients With COVID-19	Active, not recruiting	Phase 2	Nov/15/2020	Mar/31/2022
Alternative id - CAP-1002-COVID-19-02 Interventions - Biological: CAP-1002\|Biological: Placebo Study type - Interventional Study results - No Results Available Locations - Cedars-Sinai Medical Center, Los Angeles, California, United States\|University of California Davis, Sacramento, California, United States\|Henry Ford Health System, Detroit, Michigan, United States\|PharmaTex Research, LLC, Amarillo, Texas, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 63 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Number of all-cause mortality cases\|Efficacy of CAP-1002 on Cytokine\|Efficacy of CAP-1002 on Laboratory Biomarker